Cost of Disease Progression in Diffuse Large B-cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

We present results from two independent, retrospective, real-world cohort analyses to determine the cost of disease progression after first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).

Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2023 Category: Hematology Authors: John M. Burke, Anthony Masaquel, Rongrong Wang, Farah Hossain, Jia Li, Summera Qiheng Zhou, Carmen D. Ng, Matthew Matasar Tags: Original Study Source Type: research